ClinicalTrials.gg
Not yet recruitingNCT06762223Updated Jan 7, 2025

Henagliflozin on Liver Fibrosis in Patients with MASLD and T2DM

A Phase 4 interventional study of Henagliflozin 10 mg daily and Metformin 1700 mg daily in Metabolic Dysfunction-associated Steatotic Liver Disease and Type 2 Diabetes Mellitus, sponsored by Xiqiao Zhou. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by Xiqiao Zhou · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies testing henagliflozin in Diabetes Mellitus, Type 2 — 5 open to participants now, 5 under way, none of them phase 3. henagliflozin · Diabetes Mellitus, Type 2.

Planned enrollment
5th of 19
190 · median 64
Started
2024
with 3 others
Phase 4
5 of 19
4 open now
Registered
18th of 19
by date
Lead sponsor
1 of 19
Xiqiao Zhou

Among the 19 studies testing henagliflozin in Diabetes Mellitus, Type 2, this one is the 5th largest by planned enrollment, is one of 4 that started in 2024, is one of 5 in phase 4, and was the 18th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 19 studies testing henagliflozin in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About henagliflozin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing henagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing due to changes in economic conditions and lifestyle, and it is anticipated to become a significant liver disease burden in the future. This is particularly true for patients with MASLD who also have type 2 diabetes mellitus (T2DM), as the rate of comorbidity between these conditions has risen in recent years due to their shared mechanisms, necessitating careful management of both. Liver fibrosis is a critical concern, as poor blood glucose control can worsen liver fibrosis, which in turn complicates blood sugar management. Therefore, addressing liver fibrosis in patients with MASLD and T2DM is urgent, yet there are currently no targeted therapies to reverse its progression. SGLT2 inhibitors, have shown promise in potentially reversing liver fibrosis, but existing research is limited and has not adequately focused on liver fibrosis improvement, highlighting the need for more robust evidence-based studies.

03

Conditions studied

  • Metabolic Dysfunction-associated Steatotic Liver Disease
  • Type 2 Diabetes Mellitus

Keywords

  • metabolic dysfunction-associated steatotic liver disease
  • type 2 diabetes mellitus
  • Henagliflozin
  • SGLT2i
  • Liver fibrosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be aged between 18 and 75 years.
  2. Participants must meet the diagnostic criteria for MASLD and T2DM.
  3. Participants' level between 6.5% and 9%.
  4. The LSM obtained via the FibroScan device must be equal to or greater than 8 kPa.
  5. Participants must not have experienced a significant change in body weight exceeding 15% within the past four weeks.
  6. Participants must not have utilized non-biguanide hypoglycemic medications in the three months preceding the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients diagnosed with non-MASLD, which encompasses conditions such as viral hepatitis, liver disease, liver tumors, and drug-induced liver injury, among others;
  2. Individuals exhibiting and/or AST levels that exceed the normal range by threefold or more;
  3. Patients currently using or having used medications associated with secondary MASLD (including, but not limited to, , estrogen, amiodarone, methotrexate, etc.) within the preceding three months;
  4. Individuals utilizing or having utilized medications within the last three months that possess the potential to ameliorate hepatic steatosis or fibrosis in MASLD (including, but not limited to, ursodeoxycholic acid, bicyclol tablets, silymarin capsules, polyene phosphatidylcholine capsules, vitamin E, etc.);
  5. Patients with known or suspected elevated alcohol consumption (females exceeding 12 grams per day; males exceeding 24 grams per day) or those on medications that may contribute to increased consumption;
  6. Individuals who have experienced severe acute complications such as hypoglycemia, ketoacidosis, hyperglycemia, or hyperosmolar states within the past month or during the course of medication;
  7. Patients who have undergone metabolic bariatric surgery or are currently participating in bariatric treatment;
  8. Individuals with significant primary systemic pathologies, including but not limited to respiratory, circulatory, digestive, urinary, neurological, hematological, rheumatological, endocrine diseases, tumors, or AIDS;
  9. Female participants who are pregnant, breastfeeding, or of and not employing a highly effective method;
  10. Individuals with known allergies or potential allergies to the medications utilized in this study, rendering them intolerant;
  11. Patients with a history of recurrent or severe urinary and genital tract infections;
  12. Individuals exhibiting severe cognitive impairment or mental illness that impedes their ability to cooperate;
  13. Patients currently engaged in clinical observation of other pharmacological agents.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
190 participants (estimated)

Study arms

  • Placebo comparator
    Control Group

    Placebo + Metformin 1.7g/d

    Drug: Metformin 1700 mg daily · Other: Placebo of Henagliflozin

  • Experimental
    Intervention Group

    Henagliflozin 10mg/d + Metformin 1.7g/d

    Drug: Henagliflozin 10 mg daily · Drug: Metformin 1700 mg daily

Interventions

  • DrugHenagliflozinStudies of HenagliflozinHenagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Henagliflozin (SHR3824) is a hypoglycemic agent classified as an SGLT2i, which has been independently developed by Jiangsu Hengrui Pharmaceutical Co., Ltd. (China) and Shanghai Hengrui Pharmaceutical Co., Ltd (China). It received marketing authorization in China on December 31, 2021 (ID: H20210053).The prescribed dosage of Henagliflozin is 10 mg per day, as indicated on the drug label, with administration recommended in the early morning. In instances where a participant forgot to take the medication in the morning, they were permitted to do so until 12:00 PM on the same day.

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The metformin utilized in this study is Metformin Hydrochloride Extended-release Tablets, manufactured by Bristol-Myers Squibb Company. This formulation of metformin is available in a dosage of 0.85 grams per tablet, necessitating that patients administer two tablets daily to acquire the dose of 1.7g daily, to be taken within thirty minutes prior to breakfast and dinner respectively. However, adjustments to the metformin dosage were not permitted during follow-up visits.

  • OtherPlacebo of Henagliflozin

    The placebo was supplied by the pharmaceutical company responsible for Henagliflozin, ensuring that both the placebo and Henagliflozin were indistinguishable in terms of appearance, taste, and odor, while lacking any significant pharmacological effect. Administration of the placebo was recommended to occur in the early morning.

06

What researchers measure

Primary outcomes

  1. Liver stiffness measurements (LSM) of subjects

    As determined by magnetic resonance elastography (MRE)

    Time frame: From enrollment to the treatment at 24 and 48 weeks

Secondary outcomes

  1. Efficacy Evaluation of MASLD in fibrosis

    This includes: 1. Difference from baseline in LSM of subjects based on FibroScan; 2. The proportion of LSM of subjects on MRE reduced by ≥15%; 3. The proportion of LSM of subjects on FibroScan reduced by ≥15%

    Time frame: From enrollment to the treatment at 24 and 48 weeks

  2. Efficacy Evaluation of MASLD in liver fatty quantification

    This includes: 1. Difference from baseline in liver fatty quantification of subjects based on magnetic resonance imaging proton density fat fraction(MRI-PDFF); 2. Difference from baseline in liver fatty quantification of subjects based on FibroScan; 3. The proportion of liver fatty quantification of subjects based on MRI-PDFF was reduced by ≥30%; 4. The proportion of liver fatty quantification of subjects based on FibroScan was reduced by ≥30%;

    Time frame: From enrollment to the treatment at 24 and 48 weeks

  3. Efficacy Evaluation of MASLD in non-invasive biological indicators related to liver fibrosis

    This includes:1.NAFLD fibrosis score(NFS) = - 1.675 + \[0.037 ×Age\] + \[0.094 × body mass index(BMI) (kg/m2)\] + \[1.13 × fasting plasma glucose(FPG)/ Diabetes (Yes=1,No= 0)\] + \[0.99 × aspartate aminotransferase(AST)/alanine aminotransferase(ALT)\] - \[0.013 × platelet count(PLT) (×109/L)\] - \[0.66 × Albumin(ALB) (g/dL)\]; NFS \<-1.455, -1.455-0.675, and \>0.675 mean expressed as low, medium, and high risk, respectively(39); 2.Fibrosis-4(FIB-4) index= \[Age× AST (U/L)\]/\[PLT (×109/L)× ALT (U/L)1/2\];

    Time frame: From enrollment to the treatment at 24 and 48 weeks

  4. Renal function

    This includes:This includes:Difference from baseline in renal function related parameters of subjects, primarily including uric acid(UA), urea nitrogen(BUN), creatinine(Cr), urine albumin-to-creatinine ratio(UACR).

    Time frame: From enrollment to the treatment at 24 and 48 weeks

  5. Liver function

    This includes:Difference from baseline in liver function related parameters of subjects, primarily including AST, ALT, gamma-glutamyl transferase(GGT), alkaline phosphatase(ALP), ALB, total bilirubin(TBiL).

    Time frame: From enrollment to the treatment at 24 and 48 weeks

  6. Lipid metabolism

    This includes:Difference from baseline in lipid metabolism related parameters of subjects, primarily including Triglyceride(TG), total cholesterol(TC), low-density lipoprotein cholesterol(LDL-C), high-density lipoprotein cholesterol(HDL-C).

    Time frame: From enrollment to the treatment at 24 and 48 weeks

  7. Efficacy Evaluation of T2DM

    FPG

    Time frame: From enrollment to the treatment at 24 and 48 weeks

  8. Efficacy Evaluation of T2DM

    fasting insulin concentrations(FINS)

    Time frame: From enrollment to the treatment at 24 and 48 weeks

  9. Efficacy Evaluation of T2DM

    fasting C-peptide(FCP)

    Time frame: From enrollment to the treatment at 24 and 48 weeks

  10. Efficacy Evaluation of T2DM

    hemoglobin A1c(HbA1c)

    Time frame: From enrollment to the treatment at 24 and 48 weeks

  11. Efficacy Evaluation of T2DM

    homeostatic model assessment of insulin resistance(HOMA-IR)

    Time frame: From enrollment to the treatment at 24 and 48 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2024; primary completion for Dec 2026, 24 months later.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 24 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Jan 7, 2025
StartEst.
Dec 31, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06762223
Lead sponsor
Xiqiao Zhou
Responsible party
Xiqiao Zhou (Professor, Jiangsu Province Hospital of Traditional Chinese Medicine) — Sponsor-investigator
First posted
Jan 7, 2025
Start date
Dec 31, 2024 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 7, 2025

Study contacts

Tiansu Jiangsu province hospital of traditional chinese medicine
Contact
728294997@qq.com
025-17397952085
TIANSU LV, -
Contact
025+17397952085

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Henagliflozin

Start the discussion